Cargando…

Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma

A cooperative randomized clinical trial to compare the effectiveness of multi‐drug combination chemotherapy (VMCP, vincristine‐melphalan‐cyclophosphamide‐prednisolone) with CP (cyclophosphamide‐prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was ev...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kazuyuki, Kamiya, Osamu, Hamajima, Nobuyuki, Mizuno, Harumitsu, Kobayashi, Masahide, Hirabayashi, Noriyuki, Takeyama, Hideo, Kato, Ryoichi, Kawashima, Kohei, Nitta, Masakazu, Hotta, Tomomitsu, Utsumi, Makoto, Nagura, Eiichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 1990
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918012/
https://www.ncbi.nlm.nih.gov/pubmed/2126002
http://dx.doi.org/10.1111/j.1349-7006.1990.tb02697.x
_version_ 1783317339762065408
author Shimizu, Kazuyuki
Kamiya, Osamu
Hamajima, Nobuyuki
Mizuno, Harumitsu
Kobayashi, Masahide
Hirabayashi, Noriyuki
Takeyama, Hideo
Kato, Ryoichi
Kawashima, Kohei
Nitta, Masakazu
Hotta, Tomomitsu
Utsumi, Makoto
Nagura, Eiichi
author_facet Shimizu, Kazuyuki
Kamiya, Osamu
Hamajima, Nobuyuki
Mizuno, Harumitsu
Kobayashi, Masahide
Hirabayashi, Noriyuki
Takeyama, Hideo
Kato, Ryoichi
Kawashima, Kohei
Nitta, Masakazu
Hotta, Tomomitsu
Utsumi, Makoto
Nagura, Eiichi
author_sort Shimizu, Kazuyuki
collection PubMed
description A cooperative randomized clinical trial to compare the effectiveness of multi‐drug combination chemotherapy (VMCP, vincristine‐melphalan‐cyclophosphamide‐prednisolone) with CP (cyclophosphamide‐prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni‐ or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi‐drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi‐drug combination chemotherapy for patients with overt systemic disease.
format Online
Article
Text
id pubmed-5918012
institution National Center for Biotechnology Information
language English
publishDate 1990
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-59180122018-05-11 Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma Shimizu, Kazuyuki Kamiya, Osamu Hamajima, Nobuyuki Mizuno, Harumitsu Kobayashi, Masahide Hirabayashi, Noriyuki Takeyama, Hideo Kato, Ryoichi Kawashima, Kohei Nitta, Masakazu Hotta, Tomomitsu Utsumi, Makoto Nagura, Eiichi Jpn J Cancer Res Article A cooperative randomized clinical trial to compare the effectiveness of multi‐drug combination chemotherapy (VMCP, vincristine‐melphalan‐cyclophosphamide‐prednisolone) with CP (cyclophosphamide‐prednisolone) for the treatment of multiple myeloma was performed. When the whole group of patients was evaluated, the choice of chemotherapy (VMCP or CP) was not a significant prognostic factor associated with response or survival by uni‐ or multivariate analysis, and the difference between the survival curves of the treatment groups was only marginally significant. However, when the analysis was confined to stage III patients, the choice of chemotherapy became a significant prognostic factor associated with both response rate and survival, and the statistical difference between survival curves was significant. Taking the disease characteristics of multiple myeloma into consideration, the better result obtained with multi‐drug combination chemotherapy in the treatment of stage III patients is consistent with other studies supporting the superiority of multi‐drug combination chemotherapy for patients with overt systemic disease. Blackwell Publishing Ltd 1990-12 /pmc/articles/PMC5918012/ /pubmed/2126002 http://dx.doi.org/10.1111/j.1349-7006.1990.tb02697.x Text en
spellingShingle Article
Shimizu, Kazuyuki
Kamiya, Osamu
Hamajima, Nobuyuki
Mizuno, Harumitsu
Kobayashi, Masahide
Hirabayashi, Noriyuki
Takeyama, Hideo
Kato, Ryoichi
Kawashima, Kohei
Nitta, Masakazu
Hotta, Tomomitsu
Utsumi, Makoto
Nagura, Eiichi
Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title_full Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title_fullStr Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title_full_unstemmed Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title_short Multi‐drug Combination Therapy with Vincristine‐Melphalan‐Cyclophosphamide‐Prednisolone Was More Effective than Cyclophosphamide‐Prednisolone in Stage III Myeloma
title_sort multi‐drug combination therapy with vincristine‐melphalan‐cyclophosphamide‐prednisolone was more effective than cyclophosphamide‐prednisolone in stage iii myeloma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918012/
https://www.ncbi.nlm.nih.gov/pubmed/2126002
http://dx.doi.org/10.1111/j.1349-7006.1990.tb02697.x
work_keys_str_mv AT shimizukazuyuki multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT kamiyaosamu multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT hamajimanobuyuki multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT mizunoharumitsu multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT kobayashimasahide multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT hirabayashinoriyuki multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT takeyamahideo multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT katoryoichi multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT kawashimakohei multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT nittamasakazu multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT hottatomomitsu multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT utsumimakoto multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma
AT naguraeiichi multidrugcombinationtherapywithvincristinemelphalancyclophosphamideprednisolonewasmoreeffectivethancyclophosphamideprednisoloneinstageiiimyeloma